Mid-Atlantic BioTherapeutics (MABT; mid-atlanticbio.com) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body's own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. In addition, MABT continues to explore other treatment options for infectious diseases, including small molecule and antibody approaches.
View Top Employees from Mid-Atlantic BioTherapeutics| Website | http://mabt.us |
| Revenue | $5 million |
| Employees | View employees |
| Founded | 2011 |
| Address | 3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US |
| Phone | (215) 266-2301 |
| Industry | Business Services General, Pharmaceuticals, Business Services, Drug Discovery |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325414 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Mid-Atlantic BioTherapeutics employee's phone or email?
Mid-Atlantic BioTherapeutics Questions
The Mid-Atlantic BioTherapeutics annual revenue was $5 million in 2024.
Mid-Atlantic BioTherapeutics is based in Doylestown, Pennsylvania.
The NAICS codes for Mid-Atlantic BioTherapeutics are [32, 325414, 32541, 325, 3254].
The SIC codes for Mid-Atlantic BioTherapeutics are [28, 283].
